Search Results
Sep 09, 2026, 07:00 ET Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
FGFR3 inhibitor in development for LG UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor, in the
More news about: Tyra Biosciences
Sep 08, 2026, 16:05 ET Tyra Biosciences to Present at the Cantor Global Healthcare Conference
intermediate-risk non-muscle invasive bladder cancer and achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor, in the
More news about: Tyra Biosciences
Sep 04, 2026, 08:00 ET Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor, in the
More news about: Tyra Biosciences
Aug 04, 2026, 16:05 ET Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
Jul 16, 2026, 10:01 ET NASH Treatment Market Accelerates as Rezdiffra and Wegovy Establish Fibrosis-Defined Drug Pathways, Says Strategic Market Research
MarketThe availability of approved therapies has not reduced investment in NASH drug development. Competition is expanding across incretin therapies, FGF21 analogues, PPAR agonists, thyroid hormone receptor-beta agonists, glucagon-based combinations, and potential combination regimens.Eli Lilly's
More news about: Strategic Market Research LLP
Jul 08, 2026, 06:30 ET Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
proteins include:FGF-4 Heat Stable – Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity.FGF-7 Heat Stable – Engineered to support epithelial
More news about: Bio-Techne Corporation
Jun 26, 2026, 11:00 ET Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
identified a 30% reduction in MYL3 and a 50% reduction in MYOD1 (circulating markers of heart muscle and cell damage), alongside a 2.4-fold increase in FGF16 and a 2.1-fold increase in TSPAN7 (cardioprotective and tissue repair proteins) with ifetroban treatment compared with placebo. These confirmatory
More news about: Cumberland Pharmaceuticals Inc.
May 21, 2026, 08:00 ET TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRA), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with a concurrent inhibition of FGF-receptor substrate
More news about: Eisai Inc.
May 17, 2026, 21:13 ET El Día de la Innovación de ACROBiosystems llega a Zúrich
ejemplos concretos, incluyendo una citocina optimizada por IA que logró un aumento de 20 veces en el rendimiento de expresión, un mutante termoestable de FGF2 que permanece completamente activo después de tres días a 37°C, y un anticuerpo altamente específico capaz de distinguir Claudina18.2 de Claudina18.1
More news about: ACROBiosystems Group
May 17, 2026, 21:12 ET ACROBiosystems Innovation Day in Zürich bringt führende Köpfe zur Erkundung neuer Biotech-Grenzen zusammen
konkrete Beispiele hervor, darunter ein KmI-optimiertes Zytokin, das eine 20-fache Steigerung der Expressionsausbeute erzielte, eine thermostabile FGF2-Mutante, die nach drei Tagen bei 37 °C noch voll aktiv ist, und einen hochspezifischen Antikörper, der Claudin18.2 von Claudin18.1 ohne Kreuzreaktivität
More news about: ACROBiosystems Group
May 17, 2026, 21:10 ET Zurich accueille la journée de l'innovation d'ACROBiosystems : les plus grands esprits s'unissent pour explorer les frontières de la biotechnologie
présenté des exemples concrets, notamment une cytokine optimisée par l'IA dont le rendement d'expression a été multiplié par 20, un mutant thermostable du FGF2 qui reste pleinement actif après trois jours à 37°C, et un anticorps hautement spécifique capable de distinguer la Claudin18.2 de la Claudin18.1 sans
More news about: ACROBiosystems Group
May 14, 2026, 08:48 ET Peopoly Disrupts Industrial 3D Printing with the Launch of the Giga 800 FGF Printer, Slashing Material Costs by 90%
Giga 800. This groundbreaking Fused Granular Fabrication (FGF) 3D printer is designed to bridge the gap between desktop simplicity and industrial-scale manufacturing. Featuring a massive 800x800x800mm build volume
More news about: Peopoly
May 13, 2026, 08:00 ET Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
May 12, 2026, 03:04 ET ACROBiosystems Innovation Day Lands in Zurich: Top Minds Unite to Explore Biotech Frontiers
optimization. She highlighted concrete examples, including an AI-optimized cytokine that achieved a 20-fold increase in expression yield, a thermostable FGF2 mutant that remains fully active after three days at 37°C, and a highly specific antibody capable of distinguishing Claudin18.2 from Claudin18.1 with
More news about: ACROBiosystems Group
May 07, 2026, 16:05 ET Tyra Biosciences to Participate in Upcoming Investor Conferences
risk non-muscle invasive bladder cancer and achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
Apr 28, 2026, 10:00 ET ACROBiosystems Showcases AI-Driven Innovation at AACR 2026, Empowering Next-Generation Biologics Discovery
solubility. Focused on cell and gene therapy, it has been used to develop essential GMP-grade materials such as the Salt Active GENIUS™ Nuclease, Human FGF basic Superior Stable Mutant Protein, and Human IL-21 Superior Stable Mutant Protein to overcome technical bottlenecks.This AI-driven focus is
More news about: ACROBiosystems Inc.; ACROBiosystems Group
Apr 21, 2026, 07:00 ET Pharmactive Launches Kyoh® for Hair Growth Support
factor "FGF7" was also activated. This protein contributes to keratinocyte proliferation critical for keratin formation, the main material of the hair strand. In addition, an antioxidant regulator, NRF2, which pre-conditions cells to boost their resistance to oxidative stress was activated. FGF7 also sends
More news about: Pharmactive Biotech Products, S.L.U.
Apr 17, 2026, 08:00 ET Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
Apr 07, 2026, 09:00 ET Ford Foundation Announces 2026 Cohort of Ford Global Fellowship
leaders. By co-creating this catalytic experience with the leaders themselves, the program design is powered by their collective wisdom. The vibrant FGF community of practice unites people from disparate fields, including artists, engineers, scientists, lawyers, entrepreneurs, teachers, and activists,
More news about: Ford Foundation
Mar 31, 2026, 22:02 ET Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma
patients exhibit FGF19 overexpression, and this subgroup tends to derive limited benefit from first-line targeted immunotherapy combinations. As there are no approved therapies targeting the FGFR4/FGF19 signaling pathway, significant unmet medical needs remain for patients with FGF19 overexpression under
More news about: Abbisko
Mar 02, 2026, 16:05 ET Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
Feb 23, 2026, 17:30 ET Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
invasive bladder cancer, and BEACH301 for pediatric achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
Feb 19, 2026, 16:05 ET Tyra Biosciences to Participate in Upcoming Investor Conferences
non-muscle invasive bladder cancer and pediatric achondroplasia. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in
More news about: Tyra Biosciences
Feb 17, 2026, 11:42 ET Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research
numerous recombinant proteins, including key cytokines, growth factors, and cell culture reagents, such as IL-2, IL-4, IL-7, IL-15, SCF, VEGF, FGF basic/FGF2, TGF-β1, TGF-β3, and more, presented alongside legacy versions for direct comparison.The initiative supports a streamlined transition from
More news about: Persistence Market Research Pvt. Ltd.